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Abstract
Background: Butein (3,4,2',4'-tetrahydroxychalone), a plant polyphenol, is a major biologically
active component of the stems of Rhus verniciflua Stokes. It has long been used as a food additive in
Korea and as an herbal medicine throughout Asia. Recently, butein has been shown to suppress the
functions of fibroblasts. Because fibroblasts are believed to play an important role in promoting the
growth of breast cancer cells, we investigated the ability of butein to inhibit the clonogenic growth
of small numbers of breast cancer cells co-cultured with fibroblasts in vitro.
Methods: We first measured the clonogenic growth of small numbers of the UACC-812 human
breast cancer cell line co-cultured on monolayers of serum-activated, human fibroblasts in the
presence of butein (2 µg/mL) or various other modulators of fibroblast function (troglitazone-1 µg/
mL; GW9662-1 µM; meloxican-1 µM; and 3,4 dehydroproline-10 µg/mL). In a subsequent
experiment, we measured the dose-response effect on the clonogenic growth of UACC-812 breast
cancer cells by pre-incubating the fibroblasts with varying concentrations of butein (10 µg/ml-1.25
µg/mL). Finally, we measured the clonogenic growth of primary breast cancer cells obtained from
5 clinical specimens with normal fibroblasts and with fibroblasts that had been pre-treated with a
fixed dose of butein (2.5 µg/mL).
Results: Of the five modulators of fibroblast function that we tested, butein was by far the most
potent inhibitor of clonogenic growth of UACC-812 breast cancer cells co-cultured with
fibroblasts. Pre-treatment of fibroblasts with concentrations of butein as low as 2.5 µg/mL nearly
abolished subsequent clonogenic growth of UACC-812 breast cancer cells co-cultured with the
fibroblasts. A similar dose of butein had no effect on the clonogenic growth of breast cancer cells
cultured in the absence of fibroblasts. Significantly, clonogenic growth of the primary breast cancer
cells was also significantly reduced or abolished when the tumor cells were co-cultured with
fibroblasts that had been pre-treated with a fixed dose of butein.
Conclusion: We conclude that fibroblasts pre-treated with non-toxic doses of butein (a natural
herbal compound) no longer support the clonogenic growth of small numbers of primary breast
cancer cells seeded into co-cultures. These results suggest that interference with the interaction
between fibroblasts and breast cancer cells by the natural herbal compound, butein, should be
further investigated as a novel experimental approach for possibly suppressing the growth of
micrometastases of breast cancer.
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Background
Butein (3,4,2',4'-tetrahydroxychalone-Figure 1), a plant
polyphenol, is one of the major biologically active com-
ponents of the bark and stems of Rhus verniciflua Stokes.
In Far Eastern countries such as Korea, Japan, and China,
the compound has been traditionally used for treatment
of pain, thrombotic disease, gastritis, stomach cancer, and
parasitic infections [1,2]. In Korea, it has also long been
used as a food additive [2].
Recently, butein has been shown to possess potent activity
against fibroblast function [3], possibly related to its abil-
ity to suppress differentiation of fibroblasts to myofibrob-
lasts that are characteristically involved in wound healing
[4]. Because fibroblasts and myofibroblasts are now
believed to play a critical role in promoting the growth of
cancer cells [5,6], we performed this study to determine if
butein could suppress the growth of human breast cancer
cells co-cultured with fibroblasts by interfering with the
function of the fibroblasts.
Methods
Clonogenic assay
The UACC-812 human breast cancer cell line (ATCC,
Manassas, VA) was passaged in Leibovitz's medium sup-
plemented with 15% fetal calf serum. Normal fibroblasts
(CCD-1068SK, ATCC) obtained from the breast of a 65
year old female were passaged at 37°C in minimal essen-
tial medium (Eagle's) supplemented with 2 mM L-
glutamine, Earle's balanced salt solution (1.5 grams/
Liter), sodium bicarbonate, 0.1 mM non-essential amino
acids, 1 mL sodium pyruvate, and 10% fetal calf serum in
a 5% CO2  atmosphere. All cell culture reagents were
obtained from ATCC. Our co-culture experiments used
confluent monolayers of fibroblasts that had been pas-
saged no more than 21 days. This precaution assured that
the fibroblasts were not senescent or transformed.
We seeded 100 UACC-812 breast cancer cells into individ-
ual wells of a 96-well cell culture plate containing a con-
fluent monolayer of fibroblasts growing in minimal
essential growth medium supplemented as described
above. At intervals of 3–4 days, fresh medium was added.
After 14 days, the cells were fixed with 70% ethanol for 10
minutes prior to staining for 3 minutes with 0.1% toluid-
ine blue. The wells were then washed with distilled water,
and the numbers of colonies of tumor cells containing
eight or more confluent cells were counted using inverted
microscopy. Each experiment was performed in triplicate,
and the means and standard deviations for each treatment
and control group were then compared using a two-tailed,
unpaired t-test.
Co-culture with fibroblast modulators (Experiment 1)
A monolayer of normal fibroblasts was seeded with 100
UACC-812 tumor cells/well containing complete culture
medium (control) or medium supplemented with various
modulators of fibroblast function. The fibroblast modula-
tors that we tested included troglitazone (an activator of
PPAR-γ  in fibroblasts [7]; 1 µg/mL); GW9662 (an inhibi-
tor of PPAR-γ [8,9]; 1 µM); butein (an inhibitor of myofi-
broblast differentiation; 2 µg/mL); meloxican (a COX-2
inhibitor in fibroblasts [10,11]; 1 µM); or 3,4 dehydroy-
proline (an inhibitor of collagen synthesis by fibroblasts
[12]; 10 µg/mL). Because butein is relatively insoluble in
aqueous solution, it was first dissolved in dimethylsulfox-
ide to produce a stock solution (10 mg/mL) that was then
serially diluted into growth medium to produce the final
desired concentrations of butein. At intervals of 3–4 days,
old medium was removed and replaced with fresh
medium containing the drugs. After 14 days, the numbers
of colonies of 12 or more tumor cells were counted as
described above. As a control to determine the effects of
butein on the clonogenic growth of breast cancer cells in
the absence of fibroblasts, we seeded 100 tumor cells into
wells without fibroblasts but containing butein (2 µg/mL)
Co-culture with fibroblasts pre-treated with butein 
(Experiment 2)
In the next experiment, we sought to determine if pre-
treatment of fibroblasts alone with various doses of
butein would also inhibit clonogenic growth of breast
cancer cells. A monolayer of fibroblasts in individual wells
of 96-well plates was incubated for 3 days with growth
medium containing serial, 2-fold dilutions of butein rang-
ing from 10 µg/mL to 1.25 µg/mL. The adherent fibrob-
lasts were then washed three times to remove any residual
Chemical structure of butein Figure 1
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butein, and 100 UACC-812 cells were seeded per well. The
co-culture was then incubated in culture medium without
butein for 14 days, after which the numbers of colonies of
tumor cells were counted as described above.
Co-culture of primary breast cancer cells with fibroblasts 
(Experiment 3)
This experiment was performed in order to determine if
butein could also suppress the clonogenic growth of pri-
mary breast cancer cells obtained directly from clinical
specimens of human breast cancer. After obtaining appro-
priate approval from the Institutional Review Board to
perform the study in compliance with the Helsinki Decla-
ration, we aseptically dissected small fragments of tumor
tissue from five cases of invasive ductal adenocarcinoma
of the breast. These specimens were submitted for routine
diagnostic evaluation to the Surgical Pathology Depart-
ment at UCI Medical Center (Orange, CA). The tissues
were carefully minced into small pieces and then digested
overnight at 37°C in collagenase II (900 U/mL; Sigma-
Aldrich, St. Louis, MO) solution in cell culture medium.
Epithelial cells and organoids were then isolated by differ-
ential centrifugation of the digest [13], washed, and
counted. We then seeded 100 tumor cells onto monolay-
ers of fibroblasts that had been pre-treated with butein
(2.5  µg/mL) for 3 days as described in the preceding
experiment. The co-cultures were then incubated in cul-
ture medium without butein for 14 days, after which the
numbers of colonies of tumor cells were counted as
described above.
Results
Clonogenic assay
Co-culture of 100 UACC-812 human breast cancer cells
on a monolayer of human fibroblasts without butein
treatment typically yielded 50–75 distinct colonies of eas-
ily recognizable tumor cells on a background of fibrob-
lasts (Figure 2). If a monolayer of fibroblasts was not used,
an average of five small colonies of tumor cells was gener-
ally observed.
Co-culture with fibroblast modulators
The results of Experiment #1 are presented in Figure 3.
Only GW9662 and butein significantly (p < 0.01) reduced
clonogenic growth compared to the control (cell culture
medium alone with no drug). There was only one small
colony of tumor cells visible in one of three wells contain-
ing butein. Surviving individual tumor cells were not visi-
ble in any of the wells containing butein. Notably, in the
absence of fibroblasts, there was an average of 4 colonies
of tumor cells regardless of the presence or absence of
butein. Thus, butein had no detectable effect on the clo-
nogenic growth of breast cancer cells grown in the absence
of fibroblasts.
Representative colony of tumor cells in clonogenic assay Figure 2
Representative colony of tumor cells in clonogenic 
assay. Breast cancer cells co-cultured with fibroblasts typi-
cally formed clusters of confluent cells and were easily distin-
guished from the fibroblasts when stained with 0.1% toluidine 
blue. Original magnification 400×.
Co-culture of breast cancer cells and fibroblasts with drugs  that modulate fibroblasts Figure 3
Co-culture of breast cancer cells and fibroblasts with 
drugs that modulate fibroblasts. Compared to the Con-
trol (no drugs), butein and GW9662 almost completely elim-
inated clonogenic growth of the breast cancer cells.
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Co-culture with fibroblasts pre-treated with butein
The results of Experiment #2 are presented in Figure 4.
There was no clonogenic growth when 100 UACC-812
breast cancer cells were seeded onto monolayers of fibrob-
lasts that had been pre-treated for 3 days with butein at 10
or 5 µg/mL, and clonogenic growth was significantly
reduced at butein concentrations as low as 2.5 µg/mL.
Co-culture of primary breast cancer cells with fibroblasts 
pre-treated with butein
The results of Experiment #3 using primary breast cancer
cells are presented in Table 1. For each of the 5 clinical
specimens that we tested, there were significantly fewer
colonies of breast cancer cells when the co-culture was
performed in the presence of fibroblasts that had been
pre-treated with butein.
Discussion
Clonogenic growth of small numbers of breast cancer cells
in vivo [5,6] as well as in our in vitro culture system appears
to be critically dependent on the presence of fibroblasts.
In this study, we have demonstrated that butein can sup-
press the clonogenic growth of breast cancer cells in vitro
through an indirect mechanism that involves interfering
with the function of co-cultured fibroblasts. Significantly,
the concentration of butein that we found to be effective
in these experiments (2.5 µg/ml) does not significantly
reduce fibroblast viability [4] and is also non-toxic in ani-
mal experiments [1,2]. Moreover, this concentration of
butein had no significant effect on the clonogenic growth
of breast cancer cells cultured in the absence of fibroblasts.
Previous studies have shown that higher concentrations of
butein extract from Rhus verniciflua Stokes are directly
cytotoxic in vitro to human colon adenocarcinoma cells
and lymphoma cells [2,14]. Butein has also been shown
to inhibit cell growth and induce apoptosis in murine B16
melanoma cells [15]. The mechanism of induction of
apoptosis in tumor cells appears to be related to increased
caspase-3 activity, decreased Bcl-2 expression, and
increased Bax expression [16]. Butein has also been
shown to have multiple other activities, including inhibi-
tion of epidermal growth factor receptors [17], tyrosine
kinase inhibition [18], suppression of E-selectin
expression [19], inhibition of tyrosinase enzymes [20],
and inhibition of cyclooxygenase-2 [21].
Our results suggest that butein may also suppress the
growth of tumor cells through a second, indirect mecha-
nism that does not involve direct toxicity to the tumor
cells themselves. At this time, however, the precise molec-
ular mechanisms by which butein interferes with the
interaction between fibroblasts and breast cancer cells
remain undefined.
Co-culture of breast cancer cells with fibroblasts pre-treated  with butein Figure 4
Co-culture of breast cancer cells with fibroblasts pre-
treated with butein. Pre-treatment of the fibroblasts with 
butein at concentrations greater than or equal to 2.5 µg/mL 
completely eliminated or substantially reduced clonogenic 
growth of co-cultured breast cancer cells, suggesting an indi-
rect mechanism of action that interferes with the interaction 
between fibroblasts and breast cancer cells.
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Table 1: Clonogenic growth of primary breast cancer cells co-cultured with fibroblasts pre-treated with butein (2.5 µg/mL).
Clinical Sample # Mean number of colonies with butein pre-
treatment (1 s.d.)
Mean number of colonies without butein pre-
treatment (1 s.d.)
1 0 (0) 13 (4)*
2 0 (0) 36 (9)*
3 0 (0) 6 (4) *
4 3 (2) 12 (5)*
5 7 (4) 29 (8)*
*p value < 0.02 by two-tailed, unpaired t-test comparing means and s.d. of butein pre-treatment versus no pre-treatmentPublish with BioMed Central    and   every 
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Conclusion
Clonogenic growth of small numbers of breast cancer cells
co-cultured with fibroblasts pre-treated with butein is
markedly reduced. These results suggest that butein can
inhibit the growth of tumor cells through an indirect
mechanism that interferes with the interaction between
fibroblasts and breast cancer cells. Our results also suggest
that the herbal compound butein should be further
investigated as a potentially useful experimental approach
for suppressing the growth of small numbers of breast
cancer cells in early micrometastases.
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PPAR-peroxisome proliferation activator receptor
COX-cyclooxygenase
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